Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 111 articles:
HTML format



Single Articles


    November 2021
  1. GHODOUSI A, Rizvi AH, Khanzada FM, Akhtar N, et al
    In vivo Microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient.
    Eur Respir J. 2021 Nov 18. pii: 13993003.02102-2021.
    PubMed    



  2. Tuberculosis and COVID-19 co-infection: description of the global cohort.
    Eur Respir J. 2021 Nov 11. pii: 13993003.02538-2021.
    PubMed     Abstract available


  3. XIN H, Cao X, Zhang H, Feng B, et al
    Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial.
    Eur Respir J. 2021 Nov 11. pii: 13993003.02359-2021.
    PubMed     Abstract available


  4. ZHENG X, Davies Forsman L, Bao Z, Xie Y, et al
    Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug resistant tuberculosis: a multi-centre prospective cohort study in China.
    Eur Respir J. 2021 Nov 4. pii: 13993003.01925-2021.
    PubMed     Abstract available


    October 2021
  5. GUPTE AN, Kumar P, Araujo-Pereira M, Kulkarni V, et al
    Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study.
    Eur Respir J. 2021 Oct 28. pii: 13993003.00905-2021.
    PubMed     Abstract available


  6. SALUZZO F, Mantegani P, Poletti de Chaurand V, Cirillo DM, et al
    QIAreach QuantiFERON(R)-TB for the diagnosis of M. tuberculosis infection.
    Eur Respir J. 2021 Oct 21. pii: 13993003.02563-2021.
    PubMed    


    September 2021
  7. SPRUIJT I, Joren C, van den Hof S, Erkens C, et al
    Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02077-2021.
    PubMed    


  8. DECROO T, Jai K, Aung M, Hossain MA, et al
    Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02124-2021.
    PubMed    


  9. CHESOV E, Chesov D, Maurer FP, Andres S, et al
    Emergence of bedaquiline-resistance in a high-burden country of tuberculosis.
    Eur Respir J. 2021 Sep 9. pii: 13993003.00621-2021.
    PubMed     Abstract available


    August 2021
  10. MIGLIORI GB, Thong PM, Alffenaar JW, Denholm J, et al
    Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study.
    Eur Respir J. 2021 Aug 26. pii: 13993003.01786-2021.
    PubMed    


  11. LINH NN, Viney K, Gegia M, Falzon D, et al
    World Health Organization treatment outcome definitions for tuberculosis: 2021 update.
    Eur Respir J. 2021;58.
    PubMed    


    July 2021
  12. ALAGNA R, Cabibbe AM, Miotto P, Saluzzo F, et al
    Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
    Eur Respir J. 2021;58.
    PubMed    


  13. TE BRAKE LHM, de Jager V, Narunsky K, Vanker N, et al
    Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


    June 2021
  14. KHAN PY, Franke MF, Hewison C, Seung KJ, et al
    All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04345-2020.
    PubMed     Abstract available


  15. SAAVEDRA B, Mambuque E, Nguenha D, Gomes N, et al
    Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00257-2021.
    PubMed     Abstract available


  16. ORIKIRIZA P, Smith J, Ssekyanzi B, Nyehangane D, et al
    Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children.
    Eur Respir J. 2021 Jun 17. pii: 13993003.01116-2021.
    PubMed     Abstract available


  17. SHIVAKOTI R, Newman JW, Hanna LE, Queiroz ATL, et al
    Host Lipidome and Tuberculosis Treatment Failure.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04532-2020.
    PubMed     Abstract available


  18. VILLA S, Tagliani E, Borroni E, Castellotti PF, et al
    Outbreak of pre- and extensively drug-resistant tuberculosis in northern italy: urgency of cross-border, multidimensional, surveillance systems.
    Eur Respir J. 2021 Jun 3. pii: 13993003.00839-2021.
    PubMed    


  19. GUGLIELMETTI L, Varaine F
    The coming-of-age of bedaquiline: a tale with an open ending.
    Eur Respir J. 2021;57.
    PubMed    


    May 2021
  20. PENN-NICHOLSON A, Gomathi SN, Ugarte-Gil C, Meaza A, et al
    A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays.
    Eur Respir J. 2021 May 28. pii: 13993003.00526-2021.
    PubMed     Abstract available


  21. NOGUERA-JULIAN A, Buonsenso D, Mckenna L, Seddon JA, et al
    Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe.
    Eur Respir J. 2021 May 28. pii: 13993003.01196-2021.
    PubMed    


  22. VELEN K, Shingde RV, Ho J, Fox GJ, et al
    The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis.
    Eur Respir J. 2021 May 20. pii: 13993003.00266-2021.
    PubMed     Abstract available


  23. WEE LE, Goh KCM, Conceicao EP, Tan JBX, et al
    Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic.
    Eur Respir J. 2021;57.
    PubMed    


  24. GHOSH S, Breitscheidel L, Lazarevic N, Martin A, et al
    Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


  25. MAYNARD-SMITH L, Brown CS, Harris RJ, Hodkinson P, et al
    Effectiveness and outcomes of air travel-related TB incident follow-up: a systematic review.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    April 2021
  26. VEZIRIS N, Bonnet I, Morel F, Guglielmetti L, et al
    Impact of the revised definition of extensively drug resistant tuberculosis.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00641-2021.
    PubMed    


  27. MUYOYETA M, Kerkhoff AD, Chilukutu L, Moreau E, et al
    Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study.
    Eur Respir J. 2021 Apr 29. pii: 13993003.03999-2020.
    PubMed     Abstract available


  28. VAN DEUN A, Decroo T, Aung KJM, Hossain MA, et al
    Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00783-2021.
    PubMed    


  29. HAMADA Y, Cirillo DM, Matteelli A, Penn-Nicholson A, et al
    Tests for tuberculosis infection: landscape analysis.
    Eur Respir J. 2021 Apr 19. pii: 13993003.00167-2021.
    PubMed     Abstract available


  30. VINEY K, Linh NN, Gegia M, Zignol M, et al
    New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
    Eur Respir J. 2021;57.
    PubMed    


  31. SRIVASTAVA S, Gumbo T
    Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis.
    Eur Respir J. 2021;57.
    PubMed    


  32. MAITRE T, Guglielmetti L, Veziris N
    Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies.
    Eur Respir J. 2021;57.
    PubMed    


  33. NORDHOLM AC, Lillebaek T
    It is time to optimise the management of latent tuberculosis infection in children.
    Eur Respir J. 2021;57.
    PubMed    


    March 2021
  34. BOHLBRO AS, Hvingelby VS, Rudolf F, Wejse C, et al
    Active case-finding of tuberculosis in general populations and at-risk groups: a systematic review and meta-analysis.
    Eur Respir J. 2021 Mar 25. pii: 13993003.00090-2021.
    PubMed     Abstract available


  35. GUPTA RK, Lule SA, Krutikov M, Gosce L, et al
    Screening for tuberculosis among high-risk groups attending London Emergency Departments: A prospective observational study.
    Eur Respir J. 2021 Mar 18. pii: 13993003.03831-2020.
    PubMed    


  36. DE VRIES G, Gainaru D, Keizer S, Mahler B, et al
    Human reading versus computer automated reading of chest X-rays in a tuberculosis screening programme in Romania.
    Eur Respir J. 2021 Mar 10. pii: 13993003.04628-2020.
    PubMed    


  37. JOUET A, Gaudin C, Badalato N, Allix-Beguec C, et al
    Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    February 2021
  38. HEYCKENDORF J, Marwitz S, Reimann M, Avsar K, et al
    Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
    Eur Respir J. 2021 Feb 11. pii: 13993003.03492-2020.
    PubMed     Abstract available


  39. ZHANG N, Savic RM, Boeree MJ, Peloquin C, et al
    Optimising pyrazinamide for the treatment of tuberculosis.
    Eur Respir J. 2021 Feb 4. pii: 13993003.02013-2020.
    PubMed     Abstract available


  40. KOHLI M, MacLean E, Pai M, Schumacher SG, et al
    Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    January 2021
  41. HAMADA Y, den Boon S, Maria Cirillo D, Penn-Nicholson A, et al
    Framework for the evaluation of new tests for tuberculosis infection.
    Eur Respir J. 2021 Jan 21. pii: 13993003.04078-2020.
    PubMed     Abstract available


  42. SOULEYMANE MB, Piubello A, Lawan IM, Hassane-Harouna S, et al
    High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


  43. RADTKE KK, Hibma JE, Hesseling AC, Savic RM, et al
    Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
    Eur Respir J. 2021;57.
    PubMed    


    December 2020
  44. CHESOV D, Heyckendorf J, Alexandru S, Donica A, et al
    Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Eur Respir J. 2020 Dec 17. pii: 13993003.02544-2020.
    PubMed     Abstract available


    November 2020
  45. MIRZAYEV F, Viney K, Linh NN, Gonzalez-Angulo L, et al
    World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
    Eur Respir J. 2020 Nov 26. pii: 13993003.03300-2020.
    PubMed     Abstract available


  46. NIKOLAYEVSKYY V, Holicka Y, van Soolingen D, van der Werf MJ, et al
    Impact of COVID-19 pandemic on tuberculosis laboratory services in Europe.
    Eur Respir J. 2020 Nov 12. pii: 13993003.03890-2020.
    PubMed    


  47. DAVIES FORSMAN L, Niward K, Kuhlin J, Zheng X, et al
    Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
    Eur Respir J. 2020 Nov 5. pii: 13993003.03463-2020.
    PubMed    


  48. GEBRESELASSIE N, Kasaeva T, Zignol M
    A global strategy for tuberculosis research and innovation.
    Eur Respir J. 2020;56.
    PubMed    


    October 2020
  49. MANDALAKAS AM, Hesseling AC, Kay A, Du Preez K, et al
    Tuberculosis prevention in children: A prospective community based study in South Africa.
    Eur Respir J. 2020 Oct 29. pii: 13993003.03028-2020.
    PubMed     Abstract available


  50. GUPTA N, Ish P, Gupta A, Malhotra N, et al
    A profile of a retrospective cohort of 22 patients of COVID-19 with active/treated tuberculosis.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03408-2020.
    PubMed    


  51. KWON YS, Jeon D, Kang H, Yim JJ, et al
    Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: A Nationwide Cohort Study in South Korea.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03026-2020.
    PubMed    


    September 2020
  52. CHIANG CY, Islam T, Xu C, Chinnayah T, et al
    The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region (revised).
    Eur Respir J. 2020 Sep 25. pii: 13993003.03054-2020.
    PubMed    


  53. ALFFENAAR JC, Tiberi S, Cirillo DM, Migliori GB, et al
    Intermittent regimens for tuberculosis treatment: Back to the Future?
    Eur Respir J. 2020;56.
    PubMed    


    August 2020
  54. OHD JN, Hergens MP, Luksha Y, Buxbaum C, et al
    Evaluation of the latent tuberculosis screening and treatment strategy for asylum seekers in Stockholm, Sweden 2015-2018 - a record linkage study of the care cascade.
    Eur Respir J. 2020 Aug 27. pii: 13993003.02255-2020.
    PubMed     Abstract available


  55. MCQUAID CF, Cohen T, Dean AS, Houben RMGJ, et al
    Ongoing challenges to understanding multidrug and rifampicin-resistant tuberculosis in children versus adults.
    Eur Respir J. 2020 Aug 27. pii: 13993003.02504-2020.
    PubMed     Abstract available


  56. KIM HY, Ulbricht E, Ahn YK, Gillooly IS, et al
    Therapeutic drug monitoring practice in patients with active tuberculosis; assessment of opportunities.
    Eur Respir J. 2020 Aug 18. pii: 13993003.02349-2020.
    PubMed    


  57. FEUERRIEGEL S, Kohl TA, Utpatel C, Andres S, et al
    Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex(R)-MycTB.
    Eur Respir J. 2020 Aug 6. pii: 13993003.01796-2020.
    PubMed    


  58. KHURANA AK, Aggarwal D
    The (in)significance of TB and COVID-19 co-infection.
    Eur Respir J. 2020;56.
    PubMed    


    July 2020
  59. TAGLIANI E, Anthony R, Kohl TA, de Neeling A, et al
    Use of a Whole Genome Sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017-2019: an ECDC pilot study.
    Eur Respir J. 2020 Jul 30. pii: 13993003.02272-2020.
    PubMed     Abstract available


  60. CHEN H, Zhang K
    Insight into impact of COVID-19 epidemic on tuberculosis burden in China.
    Eur Respir J. 2020 Jul 30. pii: 13993003.02710-2020.
    PubMed    


  61. MAGRO P, Formenti B, Marchese V, Gulletta M, et al
    Impact of the SARS Coronavirus 2 epidemic on tuberculosis treatment outcome, Northern Italy.
    Eur Respir J. 2020 Jul 23. pii: 13993003.02665-2020.
    PubMed    


  62. HACKER B, Schonfeld N, Krieger D, Otto-Knapp R, et al
    Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany.
    Eur Respir J. 2020 Jul 6. pii: 13993003.00009-2020.
    PubMed    


  63. AVALIANI Z, Gozalov O, Kuchukhidze G, Skrahina A, et al
    What is behind programmatic treatment outcome definitions for tuberculosis?
    Eur Respir J. 2020;56.
    PubMed    


  64. MOHR-HOLLAND E, Reuter A, Hughes J, Daniels J, et al
    Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
    Eur Respir J. 2020;56.
    PubMed    


    June 2020
  65. LAU A, Sligl W, Sun K, Barrie J, et al
    Incidence and Significance of Venous Thromboembolism in Critically ill Pulmonary Tuberculosis Patients.
    Eur Respir J. 2020 Jun 25. pii: 13993003.01753-2020.
    PubMed    


  66. TADOLINI M, Garcia-Garcia JM, Blanc FX, Borisov S, et al
    On Tuberculosis and COVID-19 co-infection.
    Eur Respir J. 2020 Jun 25. pii: 13993003.02328-2020.
    PubMed    


  67. MIN ONG CW, Migliori GB, Raviglione M, MacGregor-Skinner G, et al
    Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members(#) of ESCMID Study Group for
    Eur Respir J. 2020 Jun 25. pii: 13993003.01727-2020.
    PubMed     Abstract available


  68. KWAK N, Winters N, Campbell JR, Chan ED, et al
    Changes in treatment for multidrug-resistant tuberculosis according to national income.
    Eur Respir J. 2020 Jun 25. pii: 13993003.01394-2020.
    PubMed     Abstract available


  69. MCQUAID CF, McCreesh N, Read JM, Sumner T, et al
    The potential impact of COVID-19-related disruption on tuberculosis burden.
    Eur Respir J. 2020 Jun 8. pii: 13993003.01718-2020.
    PubMed    


  70. VISCA D, Tiberi S, Pontali E, Spanevello A, et al
    Tuberculosis in the time of COVID-19: quality of life and digital innovation.
    Eur Respir J. 2020 Jun 8. pii: 13993003.01998-2020.
    PubMed    


  71. STOCHINO C, Villa S, Zucchi P, Parravicini P, et al
    Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital.
    Eur Respir J. 2020 Jun 1. pii: 13993003.01708-2020.
    PubMed    


  72. CHIANG CY, Trebucq A, Piubello A, Rieder HL, et al
    The looming threat of bedaquiline resistance in tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


    May 2020
  73. GAFAR F, Ochi T, Van't Boveneind-Vrubleuskaya N, Akkerman OW, et al
    Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data.
    Eur Respir J. 2020 May 29. pii: 13993003.01086-2020.
    PubMed     Abstract available


  74. NDJEKA N, Conradie F, Meintjes G, Reuter A, et al
    Responding to SARS-CoV-2 in South Africa: What can we learn from drug-resistant tuberculosis?
    Eur Respir J. 2020 May 29. pii: 13993003.01369-2020.
    PubMed    


  75. TADOLINI M, Codecasa LR, Garcia-Garcia JM, Blanc FX, et al
    Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
    Eur Respir J. 2020 May 26. pii: 13993003.01398-2020.
    PubMed    


  76. SAUNDERS MJ, Evans CA
    COVID-19, tuberculosis, and poverty: preventing a perfect storm.
    Eur Respir J. 2020 May 22. pii: 13993003.01348-2020.
    PubMed    


  77. HARAKA F, Schumacher SG, Ross A, Mantsoki A, et al
    Effect of history of tuberculosis on specificity of Xpert MTB/RIF.
    Eur Respir J. 2020 May 13. pii: 13993003.00343-2020.
    PubMed    


  78. VAN DEN ELSEN SHJ, Akkerman OW, Wessels M, Jongedijk EM, et al
    Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.
    Eur Respir J. 2020 May 12. pii: 13993003.00803-2020.
    PubMed    


  79. DATTA S, Gilman RH, Montoya R, Quevedo Cruz L, et al
    Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study.
    Eur Respir J. 2020 May 4. pii: 13993003.00495-2019.
    PubMed     Abstract available


  80. WONG YJ, Lee SWH
    We must screen refugees to ensure no one is left behind: a case study of Malaysia.
    Eur Respir J. 2020;55.
    PubMed    


  81. VAN DEN ELSEN SHJ, Akkerman OW, Jongedijk EM, Wessels M, et al
    Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
    Eur Respir J. 2020;55.
    PubMed    


    April 2020
  82. BASU ROY R, Thee S, Blazquez-Gamero D, Falcon-Neyra L, et al
    Performance of immune-based and microbiological tests in children with TB meningitis in Europe - a multi-center Paediatric Tuberculosis Network European Trials Group (ptbnet) study.
    Eur Respir J. 2020 Apr 16. pii: 13993003.02004-2019.
    PubMed     Abstract available


  83. BASHAM CA, Cook VJ, Johnston JC
    Towards a "fourth 90": A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985-2015.
    Eur Respir J. 2020 Apr 7. pii: 13993003.00384-2020.
    PubMed    


  84. SPRUIJT I, Erkens C, van den Hof S, Cobelens F, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.
    Eur Respir J. 2020;55.
    PubMed    


  85. VILLA S, Codecasa LR, Faccini M, Pontello MM, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.
    Eur Respir J. 2020;55.
    PubMed    


  86. ALAGNA R, Besozzi G, Codecasa LR, Gori A, et al
    Celebrating World Tuberculosis Day at the time of COVID-19.
    Eur Respir J. 2020;55.
    PubMed    


    March 2020
  87. FALZON D, Schunemann HJ, Zignol M, Mirzayev F, et al
    WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence.
    Eur Respir J. 2020;55.
    PubMed    


  88. GUGLIELMETTI L, Huerga H, Khan U, Varaine F, et al
    WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?
    Eur Respir J. 2020;55.
    PubMed    


  89. CEGIELSKI JP, Nahid P, Sotgiu G
    The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


  90. GEBRESELASSIE N, Hutubessy R, Vekemans J, den Boon S, et al
    The case for assessing the full value of new tuberculosis vaccines.
    Eur Respir J. 2020;55.
    PubMed    


  91. FIEBIG L, Beyene N, Burny R, Fast CD, et al
    From pests to tests: training rats to diagnose tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


  92. HAMADA Y, Figueroa C, Martin-Sanchez M, Falzon D, et al
    The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis.
    Eur Respir J. 2020;55.
    PubMed     Abstract available


    February 2020
  93. NIMMO C, Millard J, Brien K, Moodley S, et al
    Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients.
    Eur Respir J. 2020 Feb 14. pii: 13993003.02383-2019.
    PubMed    


    January 2020
  94. RONALD LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, et al
    Treatment with Isoniazid or Rifampin for Latent Tuberculosis Infection: Population-Based Study of Hepatotoxicity, Completion, and Costs.
    Eur Respir J. 2020 Jan 24. pii: 13993003.02048-2019.
    PubMed     Abstract available


  95. FROBERG G, Jansson L, Nyberg K, Obasi B, et al
    Screening and treatment of tuberculosis among pregnant women in Stockholm 2016-2017.
    Eur Respir J. 2020 Jan 16. pii: 13993003.00851-2019.
    PubMed     Abstract available


    December 2019
  96. JONSSON J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J, et al
    Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden.
    Eur Respir J. 2019 Dec 20. pii: 13993003.01886-2019.
    PubMed     Abstract available


  97. DE VRIES G, Commandeur S, Erkens C, Haddad W, et al
    Towards selective tuberculosis screening of people in prison in a low-incidence country.
    Eur Respir J. 2019 Dec 20. pii: 13993003.02209-2019.
    PubMed    


  98. STEK C, Allwood B, Du Bruyn E, Buyze J, et al
    The effect of HIV-associated tuberculosis, tuberculosis-IRIS, and prednisone on lung function.
    Eur Respir J. 2019 Dec 20. pii: 13993003.01692-2019.
    PubMed     Abstract available


  99. RUESEN C, Chaidir L, Ugarte-Gil C, van Ingen J, et al
    Diabetes is associated with genotypically drug-resistant tuberculosis.
    Eur Respir J. 2019 Dec 12. pii: 13993003.01891-2019.
    PubMed    


  100. BOMANJI J, Sharma R, Mittal BR, Gambhir S, et al
    PET/CT features of Extrapulmonary Tuberculosis at first clinical presentation - a cross-sectional observational (18)F-FDG imaging study across six countries.
    Eur Respir J. 2019 Dec 12. pii: 13993003.01959-2019.
    PubMed     Abstract available


  101. GENESTET C, Paret R, Pichat C, Berland JL, et al
    Routine survey of Mycobacterium tuberculosis isolates reveals nosocomial transmission.
    Eur Respir J. 2019 Dec 5. pii: 13993003.01888-2019.
    PubMed    


  102. LEE SW, Kang YA, Jin CE, Kim HC, et al
    Gene-based diagnosis of tuberculosis with a new-generation pathogen enrichment technique.
    Eur Respir J. 2019 Dec 5. pii: 13993003.01885-2019.
    PubMed    


    November 2019
  103. KERKHOFF AD, Sossen B, Schutz C, Reipold EI, et al
    Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV.
    Eur Respir J. 2019 Nov 7. pii: 13993003.01259-2019.
    PubMed    


    October 2019
  104. OLAYANJU O, Esmail A, Limberis J, Dheda K, et al
    A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis.
    Eur Respir J. 2019 Oct 16. pii: 13993003.01181-2019.
    PubMed     Abstract available


  105. BORISOV S, Danila E, Maryandyshev A, Dalcolmo M, et al
    Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
    Eur Respir J. 2019 Oct 10. pii: 13993003.01522-2019.
    PubMed     Abstract available


  106. DIEL R, Schluger NW
    Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?
    Eur Respir J. 2019;54.
    PubMed    


  107. CAMINERO JA, Garcia-Basteiro AL, Rendon A, Piubello A, et al
    The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.
    Eur Respir J. 2019;54.
    PubMed    


  108. ZELLWEGER JP
    Screening migrants for tuberculosis and latent TB infection: the reward will come later.
    Eur Respir J. 2019;54.
    PubMed    


    September 2019
  109. AHMAD BB, Kristensen KL, Glenthoj JP, Poulsen A, et al
    Latent tuberculosis infection among minor asylum seekers in Denmark.
    Eur Respir J. 2019 Sep 26. pii: 13993003.01688-2019.
    PubMed    


  110. EL ACHKAR S, Demanche C, Osman M, Rafei R, et al
    Zoonotic tuberculosis in humans assessed by next-generation sequencing: an 18-month nationwide study in Lebanon.
    Eur Respir J. 2019 Sep 26. pii: 13993003.00513-2019.
    PubMed    


  111. REEVE BWP, Centis R, Theron G
    Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals.
    Eur Respir J. 2019;54.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: